Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001129928-16-000019
Filing Date
2016-11-03
Accepted
2016-11-03 14:19:49
Documents
4
Period of Report
2016-09-30

Document Format Files

Seq Description Document Type Size
1 THIRD QUARTER 2016 thirdquarter20166k.htm 6-K 23267
2 INTERIM FINANCIAL STATEMENTS SEPTEMBER 30, 2016 ex991interimfinancialstate.htm EX-99.1 353014
3 INTERIM MD&A SEPTEMBER 30, 2016 ex992-q32016mda.htm EX-99.2 229835
4 image0a03.jpg GRAPHIC 32654
  Complete submission text file 0001129928-16-000019.txt   651951
Mailing Address 210 - 1167 KENSINGTON CRES NW CALGARY A0 T2N 1X7
Business Address 1167 KENSINGTON CRES NW SUITE 210 CALGARY ALBERTA CANADA T2N 1X7 ALBERTA CANADA A0 00000 4036707380
ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 000-31062 | Film No.: 161971130
SIC: 2834 Pharmaceutical Preparations